Loading...
CureVac N.V.
5CV.F•XETRA
Healthcare
Biotechnology
€4.68
€-0.02(-0.38%)
CureVac N.V. (5CV.F) Financial Performance & Income Statement Overview
Review CureVac N.V.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
895.54%
↑ 895.54%
Operating Income Growth
164.80%
↑ 164.80%
Net Income Growth
162.34%
↑ 162.34%
Operating Cash Flow Growth
138.02%
↑ 138.02%
Operating Margin
37.48%
↑ 37.48%
Gross Margin
87.59%
↑ 87.59%
Net Profit Margin
34.50%
↑ 34.50%
ROE
29.56%
↑ 29.56%
ROIC
28.82%
↑ 28.82%
CureVac N.V. (5CV.F) Income Statement & Financial Overview
Review CureVac N.V.'s (5CV.F) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $14.47M | $493.90M | $14.44M | $12.37M |
| Cost of Revenue | $1.49M | $21.93M | $40.72M | $41.69M |
| Gross Profit | $12.98M | $471.97M | -$26.29M | -$29.32M |
| Gross Profit Ratio | $0.90 | $0.96 | -$1.82 | -$2.37 |
| R&D Expenses | $44.14M | $49.98M | $31.09M | $27.82M |
| SG&A Expenses | $16.34M | $14.24M | $13.45M | $16.80M |
| Operating Expenses | $56.74M | $103.59M | $47.33M | $44.92M |
| Total Costs & Expenses | $58.23M | $125.52M | $88.06M | $86.61M |
| Interest Income | $3.72M | $2.33M | $2.53M | $3.77M |
| Interest Expense | -$636000.00 | $141000.00 | $155000.00 | $340000.00 |
| Depreciation & Amortization | $4.30M | $4.51M | $5.13M | $5.13M |
| EBITDA | -$34.89M | $375.23M | -$65.96M | -$72.22M |
| EBITDA Ratio | -$2.41 | $0.76 | -$4.57 | -$5.84 |
| Operating Income | -$43.76M | $368.38M | -$73.62M | -$73.32M |
| Operating Income Ratio | -$3.02 | $0.75 | -$5.10 | -$5.93 |
| Other Income/Expenses (Net) | $5.20M | $2.19M | $2.38M | $3.43M |
| Income Before Tax | -$38.56M | $370.57M | -$71.24M | -$69.89M |
| Income Before Tax Ratio | -$2.67 | $0.75 | -$4.94 | -$5.65 |
| Income Tax Expense | -$5.80M | $32.53M | $1.30M | $666000.00 |
| Net Income | -$32.76M | $338.04M | -$72.54M | -$70.55M |
| Net Income Ratio | -$2.26 | $0.68 | -$5.03 | -$5.70 |
| EPS | -$0.15 | $1.51 | -$0.32 | -$0.31 |
| Diluted EPS | -$0.15 | $1.51 | -$0.32 | -$0.31 |
| Weighted Avg Shares Outstanding | $224.35M | $224.31M | $224.31M | $224.29M |
| Weighted Avg Shares Outstanding (Diluted) | $224.79M | $224.31M | $224.31M | $224.29M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan